Here, we investigated the beneficial therapeutic effect of boosting the neurotrophic environment by initiating treatment with P021 in the diet at 3 months of age (i.e., around 6–9 months before any overt Aβ or tau pathology, and during the period of synaptic compensation) and continuing for approximately 18 months in a triple transgenic mouse model of AD (3 × Tg-AD mice). Here, MAPT is linked to Alzheimer disease.